Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.88 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153251 | 0.83 | GPBAR1 (0.62) | GPBAR1AOC3CYP17A1CYP1A2IDO1 | |
| SCHEMBL3716494 | 0.72 | GPBAR1 (0.57) | GPBAR1KCNA3BDKRB2RAB9A | |
| SCHEMBL3714728 | 0.71 | GPBAR1 (0.54) | GPBAR1KCNA3SCN9ANR2F2RAB9A | |
| SCHEMBL3721720 | 0.71 | GPBAR1 (0.54) | GPBAR1KCNA3SCN9ANR2F2RAB9A | |
| SCHEMBL15426194 | 0.69 | GPBAR1 (0.45) | GPBAR1MAPTCYP1A2IDO1 | |
| SCHEMBL3713382 | 0.65 | GPBAR1 (0.70) | GPBAR1KCNA3SCN9ANR2F2RAB9A | |
| SCHEMBL3723393 | 0.64 | GPBAR1 (0.46) | GPBAR1KCNA3BDKRB2NR2F2RAB9A | |
| SCHEMBL31364101 | 0.64 | KCNA3 (0.65) | GPBAR1KCNA3MAPTCYP1A2NR2F2 | |
| SCHEMBL5445170 | 0.64 | KCNA3 (0.65) | GPBAR1KCNA3MAPTCYP1A2NR2F2 | |
| SCHEMBL2257440 | 0.64 | GPBAR1 (0.48) | GPBAR1KCNA3NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2010117090-A1 | NOVEL ISOQUINOLINYLOXYMETHYL HETEROARYL DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117090-A1 | NOVEL ISOQUINOLINYLOXYMETHYL HETEROARYL DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | GPBAR1 15/4885KCNA3 4414/4885AOC3 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.